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Abstract
Background: Xpert MTB/RIF was introduced as a screening test for all presumptive tuberculosis cases in primary health
services in Cape Town, South Africa.
Study Aim: To compare multidrug-resistant tuberculosis (MDR-TB) treatment commencement times in MDRTBPlus Line
Probe Assay and Xpert MTB/RIF-based algorithms in a routine operational setting.
Methods: The study was undertaken in 10 of 29 high tuberculosis burden primary health facilities, selected through
stratified random sampling. An observational study was undertaken as facilities transitioned to the Xpert MTB/RIF-based
algorithm. MDR-TB diagnostic data were collected from electronic laboratory records and treatment data from clinical
records and registers. Kaplan Meier time-to-event analysis was used to compare treatment commencement time, laboratory
turnaround time and action delay between algorithms. A facility-level paired analysis was done: the median time-to-event
was estimated per facility in each algorithm and mean differences between algorithms compared using a paired t-test. Cox
proportional hazards regression was used to assess the effect of patient-level variables on treatment commencement time.
The difference between algorithms was compared using the hazard ratio.
Results: The median treatment commencement time in the Xpert MTB/RIF-based algorithm was 17 days (95% CI 13 to 22
days), with a median laboratory turnaround time (to result available in the laboratory) of ,1 day (95% CI,1 to 1 day). There
was a decrease of 25 days (95% CI 17 to 32 days, p,0.001) in median MDR-TB treatment commencement time in the Xpert
MTB/RIF-based algorithm. We found no significant effect on treatment commencement times for the patient-level variables
assessed.
Conclusion: MDR-TB treatment commencement time was significantly reduced in the Xpert MTB/RIF-based algorithm.
Changes in the health system may have contributed. However, an unacceptable level of delay remains. Health system and
patient factors contributing to delay need to be evaluated and addressed to optimise test benefits.
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Introduction
Improving multidrug-resistant tuberculosis (MDR-TB) control
requires access to accurate and rapid diagnostics for drug
susceptibility testing [1–3]. A rapid diagnosis has both patient
and public health benefits: it enables early, appropriate treatment
which can reduce morbidity and mortality for patients as well as
transmission within communities. This is of particular importance
in South Africa which has a high TB and MDR-TB burden with
349, 582 and 15,419 cases respectively reported in 2012 [4]. South
Africa’s early adoption of new molecular diagnostic tests is one of
the responses to the TB crisis: Hain-MDRTBPlus line probe assay
(LPA) was introduced following the WHO Policy statement in
2008 [5] and Xpert MTB/RIF (Xpert) following the 2011 policy
statement [6].
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The efficacy of both tests has been well established [7–12] and
confirmed by systematic reviews [13–15]. Policy recommendations
for both diagnostics have been based largely on accuracy data
from laboratory and demonstration studies. This has limitations, as
test performance under operational conditions and evidence
linking accuracy to patient important outcomes are not consid-
ered, making it difficult to translate ‘‘scientific progress into public
health impact’’ [16].
Few studies have reported on the effect of molecular diagnostics
on MDR-TB treatment delay [17–19]. Studies from South Africa
that compared conventional drug susceptibility tests (DST) to LPA
showed a reduction in median treatment commencement time
from 72 days with conventional DST to 24 days with LPA in a
demonstration study [17] and from 80 to 55 days in a rural TB
hospital [18]. Although studies have reported a reduction in
treatment delay with Xpert for drug-susceptible cases [12,20], we
are not aware of any publications that address its effect on MDR-
TB treatment delay.
This study is part of a broader PROVE IT (Policy Relevant
Outcomes from Validating Evidence on ImpacT) (http://treattb.
org) evaluation undertaken in Cape Town, South Africa, to assess
the impact of new molecular diagnostics on the diagnosis and
treatment of tuberculosis. Guided by the Impact Assessment
Framework [21], the magnitude and range of benefits for patients
(from clinical presentation to treatment initiation), the magnitude
and nature of inputs required and factors that influence policy
change were evaluated.
Study Aim
We compared MDR-TB treatment commencement times
(TCT) in LPA and Xpert-based algorithms in a routine
operational setting. Treatment non-initiation rates and the
association between MDR-TB TCT and patient level variables
such as age, sex, HIV-status, MDR-risk profile, MDR-TB
diagnostic time-point and treatment initiation site were also
assessed.
Methods
This observational cohort study compared cases in a LPA-based
algorithm to those in an Xpert-based algorithm, as facilities
transitioned to the latter in 2011–2012.
Setting
The study was undertaken in Cape Town, South Africa. The
City had a high TB burden with 28,658 TB cases and 953 MDR-
TB cases recorded in 2011 and a TB case notification rate of 752/
100,000 population (Source: J. Caldwell, Routine TB Programme
Data, Cape Town Health Directorate). Free TB diagnostic
services were provided at 142 primary health care (PHC) facilities
and treatment at 101 of these. A daily courier delivered all
specimens to a central laboratory where tests were done and
results recorded in an electronic laboratory database. Positive TB
results were faxed to facilities on a daily basis and hard copies of all
results returned by courier.
Patients diagnosed with MDR-TB received standardised
treatment regimens. Historically, patients initiated MDR-TB
treatment at a central TB-hospital. From 2005, doctors at the
TB hospital reviewed case records and prescribed treatment but
patients could initiate treatment at PHC facilities. In 2012, doctors
at the PHC facilities offering TB treatment initiated standardised
MDR-TB treatment without the need for prior review of the case
at the TB-hospital.
TB Algorithms
The health department introduced LPA as a replacement for
conventional first-line DST in January 2008. LPA was initially
performed on culture (BACTEC MGIT 960) isolates in high
MDR-risk presumptive TB cases and later also directly on smear-
positive sputa and referred to in this study as the LPA-based
algorithm (Figure 1).
From 2011 to 2013 Xpert was sequentially introduced into the
eight health sub-districts in Cape Town, replacing smear
microscopy for all presumptive TB cases and referred to in this
study as the Xpert-based algorithm (Figure 1).
In both algorithms, cases in whom 1st line regimens failed (i.e.
those with positive smears during the course of treatment and or
clinical deterioration) were evaluated for MDR-TB though culture
and LPA (Figure 1).
Study Population
This study was undertaken in a routine operational setting in 10
high TB-burden government PHC facilities, selected from a total
of 29 that met the criteria of a TB caseload of .350 in 2009. Two
facilities were excluded due to competing research studies. The
remaining facilities were ordered according to their smear-positive
treatment success rates in 2009 and five were randomly selected
from each group above and below the median.
All individuals with sputum samples taken at these facilities
between January 2008 and December 2012 and with a laboratory
diagnosis of pulmonary MDR-TB were included in the study
(Figure 2). Cases diagnosed at other public health facilities in Cape
Town that had received treatment at the selected facilities were
also included. Cases with previous MDR-TB treatment or without
results from the national health laboratory were excluded. Only
cases from the 9 facilities that transitioned to the Xpert-based
algorithm in the study period were included in the analysis.
Data Sources, Collection and Management
Patients diagnosed with MDR-TB in selected facilities were
identified from the electronic laboratory database using the facility
name and location code; those diagnosed elsewhere, but on
treatment at the selected facilities, were identified through facility
DR-TB paper registers and patient clinical records. Professional
nurses undertook clinical record reviews of all cases that met the
inclusion criteria and recorded demographic, laboratory and
clinical data on case report forms. Data were quality checked, dual
entered into a Microsoft SQL database and corrected. Where
clinical records could not be found, treatment data were extracted
from electronic in-patient records at the TB hospital and from sub-
district electronic DR-TB registers. Data from these sources were
linked to electronic laboratory data, which provided information
on the specimen tested, test dates, type of test and results.
Study data will be made available to other researchers on
request, with permission from the relevant authorities.
Definitions
In both algorithms, a specimen with rifampicin and isoniazid
resistance was defined as MDR-TB; in the Xpert-based algorithm,
rifampicin-resistance on Xpert was considered a proxy indicator of
MDR-TB.
The primary outcome measure of MDR-TB TCT was
calculated from first MDR-TB diagnostic sputum collection date
to MDR-TB treatment commencement date and comprised two
intermediary times:
1. Laboratory turnaround time was calculated from date of
sputum collection to date result was available in the laboratory.
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2. ‘Action’ delay was calculated from date result was available in
the laboratory to treatment commencement date.
Non-initiation of MDR-TB treatment was defined as no record
of treatment initiation in facility records, the electronic DR-TB
register or the in-patient hospital database within 6 months of the
MDR-TB test sputum being collected.
The MDR-TB diagnostic time-point was defined as either pre-
treatment, for a presumptive TB case being concurrently evaluated
for TB and drug resistance, or as treatment, for a case on a 1st-line
TB regimen being evaluated for drug resistance.
Low MDR-TB risk was defined as #four weeks previous TB
treatment and high MDR-TB risk as .four weeks previous TB
treatment, from congregate settings or with a known MDR-TB
contact, based on clinical records.
Statistical Analysis
Demographic characteristics were analyzed using the t-test for
normally distributed continuous outcomes and chi-square for
categorical outcomes. Kaplan Meier time-to-event analysis was
used to compare treatment commencement time, laboratory
turnaround time and action delay between algorithms. Kaplan
Meier survival distribution was used to estimate median time-to-
event, defined as the length of time corresponding to the
probability of 0.5 [22]. A facility-level paired analysis was used
to generate summary statistics: the median time-to-event was
estimated per facility and mean differences between diagnostic
algorithms compared using a paired t-test.
Cox proportional hazards regression using the Breslow method
for ties with a facility-level stratification was used to assess the
effect of patient-level variables such as age, gender, HIV-status,
MDR-TB risk profile and treatment initiation site on MDR-TB
TCT. We adjusted for these variables and used the hazard ratio to
compare the overall difference in MDR-TB TCT between
diagnostic algorithms. Analyses were undertaken using STATA
12 (StataCorp).
Ethics Statement
The City Health Directorate, Western Cape Health Depart-
ment and National Health Laboratory Service granted permission
to use the routine health data. The Health Research Ethics
Committee at Stellenbosch University (IRB0005239) (N10/09/
308) and Ethics Advisory Group at The International Union
Against Tuberculosis and Lung Disease (59/10) approved the
study. A waiver of informed consent was granted for the use of
routine data.
Results
Of the 642 MDR-TB cases identified, 541 met the criteria for
inclusion in the analysis (Figure 2). Amongst the 414 cases in the
LPA-based and 127 in the Xpert-based algorithm, there were no
significant differences in sex, age, HIV-status or MDR-TB risk
profile (Table 1). In the LPA-based algorithm, 68% were
diagnosed at the pre-treatment MDR-TB diagnostic time-point
compared to 83% in the Xpert-based algorithm (p= 0.002).
Figure 1. TB Testing in the LPA and Xpert-based Algorithms. The sequence of diagnostic tests in each algorithm and the action taken based
on test results is shown. Shaded blocks indicate possible MDR-TB diagnostic points. Abbreviations: MDR-TB - multidrug-resistant tuberculosis; LPA -
line probe assay; DST - drug susceptibility testing; HIV – human immunodeficiency virus; Rif – rifampicin; Pos – positi.
doi:10.1371/journal.pone.0103328.g001
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Non-initiation rates did not differ between the LPA (9%) and
Xpert-based algorithm (6%) (risk ratio 1.7, p = 0.167). Compar-
ative data for those who did and did not initiate treatment found
that only HIV contributed significantly to non-initiation in the
LPA-based algorithm (85% HIV-positive in the non-initiation
group compared to 57% for those on treatment, p = 0.014).
Amongst cases on MDR-TB treatment (Table 1), there were no
significant differences in sex, age, HIV-status or MDR-TB risk
profile between the algorithms. More patients initiated treatment
at PHC-level in the Xpert (98%) than in the LPA-based algorithm
(88%) (p,0.001).
There was a reduction in median time-to-event between the
LPA and Xpert-based algorithms (Table 2): MDR-TB TCT was
reduced from 43 to 17 days (Figure 3a); laboratory turnaround
time from 24 days to ,1 day (Figure 3b) and ‘action’ delay from
14 to 10 days. The facility-level paired analysis showed a difference
of 25 days (95% CI 17 to 32 days) (p,0.001) in median MDR-TB
TCT, 20 days (95% CI 14 to 27 days) (P,0.001) in median
Figure 2. Study Population. MDR-TB cases identified from selected facilities and those included and excluded from the study and from the final
analysis are shown. Abbreviations: MDR-TB – multidrug-resistant tuberculosis; DST- drug susceptibility test; TCT - treatment commencement time.
doi:10.1371/journal.pone.0103328.g002
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laboratory turnaround time and 5 days (95% CI 1 to 9 days)
(p = 0.015) in median ‘action’ delay between algorithms.
A univariate analysis showed no significant association between
MDR-TB TCT and age (p = 0.429), sex (p = 0.064) (Figure 4a),
HIV-status (p = 0.056) (Figure 4b) or treatment initiation site
(p = 0.340). There was a significant association between MDR-TB
TCT and MDR-TB risk profile (p = 0.032): TCT decreased for
both risk profiles (Figure 4c), but more so in the low-risk category
(hazard ratio (HR) 3.3, 95% CI 2.4 to 4.6, p,0.001) than the
high-risk category (HR 2.0, 95% CI 1.4–2.8, p,0.001). A
significant association was also found between MDR-TB TCT
and the MDR-TB diagnostic time-point (p = 0.001): the difference
was greater for cases at the pre-treatment diagnostic time-point
Figure 3. Cumulative Time-to-event Plots by Algorithm. Kaplan Meier time-to-event plots are shown for MDR-TB treatment commencement
time (sample taken to treatment commencement) in Figure 3a and for laboratory turnaround time (to result available in the laboratory) in Figure 3b
for cases included in the final analysis in the LPA- and Xpert-based algorithms. Abbreviation: MDR-TB - multidrug-resistant tuberculosis.
doi:10.1371/journal.pone.0103328.g003
Table 2. MDR-TB TCT, Laboratory Turnaround Time and Action Delay by Algorithm.
LPA-based Algorithm Xpert-based Algorithm
MDR-TB TCT (days) Median (95% CI) 43 (40–46) 17 (13–22)
Interquartile range 30–64 7–36
Laboratory Turnaround Time (days) Median (95% CI) 24 (22–25) ,1 (,1–1)
Interquartile range 18–33 ,1–17
Action delay (days) Median (95% CI) 14 (13–15) 10 (8–14)
Interquartile range 9–30 6–21
Median MDR-TB TCT for
different categories of
patients (days) (95% CI)
Female 43 (37–47) 14 (10–19)
Male 43 (40–47) 22 (14–29)
HIV-positive 43 (40–47) 17 (12–28)
HIV-negative 44 (36–49) 17 (8–22)
Low MDR-TB risk 42 (38–46) 14 (10–27)
High MDR-TB risk 44 (40–49) 18 (13–23)
MDR-TB diagnostic time-point:
Pre-treatment
43 (39–47) 14 (10–20)
MDR-TB diagnostic time-point:
Treatment
43 (38–48) 36 (19–51)
MDR-TB treatment initiation
TB hospital
44 (34–52) 23*
MDR-TB treatment
initiation PHC facility
43 (40–46) 16 (13–22)
Table showing median time-to-event for cases included in the final analysis in each algorithm. Abbreviations: MDR-TB TCT - Multidrug-resistant tuberculosis treatment
commencement time’ HIV - human immunodeficiency virus; CI – Confidence interval; PHC – primary health care. *95% CI not reported due to small sample (n = 2).
doi:10.1371/journal.pone.0103328.t002
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(HR 3.9, 95% CI 2.5 to 5.9, p,0.001) than at the treatment time-
point (HR 3.4, 95% CI 2.6 to 4.4, p,0.001) (Figure 4d).
However, in the extended Cox regression model that adjusted
for all these patient level variables, only the algorithm produced a
significant effect, with a hazard ratio of 2.7 (95% CI 2.1 to 3.4, p,
0.001) in the Xpert compared to LPA-based algorithm.
Discussion
This is one of the first studies to report on MDR-TB TCT in an
Xpert-based algorithm under routine operational conditions. A
reduction of 25-days in median MDR-TB TCT was found with
the introduction of the Xpert-based algorithm. Most of the gain
(80%) resulted from a reduced laboratory turnaround time with
only 20% due to a reduction in the ‘action’ delay.
In this before-and-after comparison, a range of health system
improvements that were introduced may have contributed to the
reduction in MDR-TB TCT in the Xpert-based algorithm. At
PHC-level, for example, care was fully decentralised for patients
not requiring hospitalisation. From 2012, standard MDR-TB drug
regimens were made available at PHC-level and sub-district
medical officers could initiate treatment without prior review of
cases or prescriptions from the TB-hospital. A nurse was also
employed in each of the eight sub-districts to trace MDR-TB
patients, refer to appropriate social services, arrange screening of
contacts and ensure work-up and treatment commencement.
Considering the median laboratory turnaround time of ,1 day
and the health system improvements that were introduced, the
median MDR-TB TCT of 17 days (95% CI 13 to 22 days) in the
Xpert-based algorithm showed an unexpected level of delay. This
partly reflected the time taken for pre-MDR-TB treatment clinical
requirements such as chest x-rays, liver function tests and
audiometry (done centrally at the TB hospital). Since the Xpert
algorithm was only introduced for a period of 18 months during
the study, it is possible that as the changes that have been
introduced are entrenched, further reductions in MDR-TB TCT
will be achieved.
Figure 4. Cumulative Time to MDR-TB TCT Plots for Co-variables Assessed by Algorithm. Kaplan Meier time-to-event plots are shown for
patient level variables assessed in the LPA-and Xpert-based algorithms: a) Sex; b) HIV-status; c) MDR-TB Risk Profile and d) MDR-TB Diagnostic Time-
point. Inserts show Hazard Ratio (HR) for the univariate Cox regression analysis. Abbreviations: MDR-TB - multidrug-resistant tuberculosis; TCT –
treatment commencement time.
doi:10.1371/journal.pone.0103328.g004
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Several factors may have contributed to ‘action’ delays,
including inefficiencies in accessing results and recalling patients.
‘Action’ delays have also been found in other studies. In the
Western Cape of South Africa, Jacobsen et al [18] found median
delays from result being sent to the facility to treatment
commencement of 20 days with LPA compared to 19 days with
conventional DST. In two health regions in Peru, Yagui et al [23]
showed that delays due to slow bacterial growth on solid media
and ‘‘action’’ delays at various time-points contributed equally to
the median TCT of almost 5 months. Patient factors may have
also contributed to delays [24], including patients’ failure to return
promptly for their results due to work and family commitments
and to perceptions of long waiting times and poor services.
There was no significant difference in MDR-TB treatment non-
initiation rates between algorithms, due possibly to the small
sample size in the Xpert-based algorithm. However, we found
substantially lower non-initiation rates in both algorithms than
those reported for South Africa [4,25]. The 6-month cut-off used
in our definition of non-initiation has contributed to this.
Standardisation of the definition will enable comparisons between
studies. It is unclear to what extent the changes in the health
systems may have also contributed and this requires further
investigation.
As was expected based on the health system changes, a higher
percentage of patients initiated treatment at PHC-level in the
Xpert-based than in the LPA-based algorithm (98% compared to
88%, p,0.001). An unexpected finding however in the LPA-based
algorithm was the similarity in MDR-TB TCT for patients
initiating treatment at the TB-hospital compared to at PHC-level
with a median of 44 and 43 days respectively. The need for prior
case reviews and prescriptions from the TB-hospital for those
initiating treatment at PHC-level may account for this. It is not
possible to make inferences about the impact of decentralised care
in the Xpert-based algorithm due to the small number initiating
treatment at the TB-hospital.
The extent to which vulnerable groups benefit from a new
diagnostic test is an important aspect of impact assessment [21].
The failure to find a significant reduction in MDR-TB TCT for
HIV-positive individuals in the Xpert-based algorithm is surpris-
ing. Based on the increased sensitivity of Xpert for smear-negative
TB cases [12], we expected to find that a higher proportion of
HIV-positive individuals would be diagnosed by Xpert and would
not require lengthy culture and DST. Our finding could however
be attributed to the small sample in the Xpert-based algorithm and
is a limitation of the study. There were also no benefits in MDR-
TB TCT by age or gender.
New molecular tests need to be evaluated within the context of a
diagnostic algorithm [21] and this is a unique aspect of this study.
We found that not all patients in the Xpert-based algorithm
received an Xpert test: 17% of this group were TB cases evaluated
through culture and LPA when a first-line regimen failed. Studies
that report on TCT based solely on a positive Xpert test fail to
take this and other factors into account, including cases in whom
the correct test was not requested or could not be done (due to an
inadequate sputum volume, for example).
Whilst an operational evaluation provides important insights
into the benefits possible in real-world settings, it has limitations.
The quality and completeness of routine data is the first of these.
Clinical records did not provide adequate information to assess the
time between the onset of symptoms and MDR-TB testing. The
25-day reduction in TCT needs to be viewed in relation to this
delay.
Another limitation of the study is that MDR-TB TCT was
calculated from the point at which the MDR-TB test was taken
and not necessarily the starting point on the algorithm. Treatment
delay was thus potentially underestimated in the LPA-based
algorithm as new TB cases did not have initial DST and may have
had undiagnosed primary MDR-TB when evaluated for TB. We
also did not assess the impact of the algorithm on MDR-TB
treatment outcomes.
The extent to which our results can be generalised is limited by
the setting: all facilities in the study were urban or peri-urban;
Cape Town has a relatively good laboratory and health
infrastructure with access to rapid liquid culture and decentralised
MDR-TB treatment. During the study period all tests were done
at a central laboratory. Additional evidence is therefore required
from studies in rural settings, where liquid culture is not available
and where there is decentralised use of Xpert, to provide a broader
understanding of potential benefits.
In South Africa, where Xpert has been introduced as a
replacement for smear microscopy, annual TB diagnostic costs are
estimated to increase by 53–57% to USD 48–70 million per year
at full Xpert coverage [26]. The reduced MDR-TB TCT in the
Xpert-based algorithm needs to be assessed within the context of
the cost-effectiveness of the algorithm. A more thorough under-
standing of impact also requires an assessment of other potential
benefits including, for example, TB yield, treatment outcomes and
benefits from a patient’s perspective.
Conclusion
We require evidence that new diagnostic tests which perform
well in controlled settings can have an impact when implemented
in operational settings [27]. This study showed that median MDR-
TB TCT was reduced by 25 days with the introduction of an
Xpert-based algorithm in a routine operational setting. However,
when considered against a median laboratory turnaround time of
,1-day, the median TCT of 17-days in the Xpert-based algorithm
showed an unacceptable level of delay, exceeding the national
target of five days [28].
Despite the substantial investment in the new technology [26],
patients did not benefit fully from the use of Xpert, due possibly to
both health system and patient factors. These need to be evaluated
and addressed. Strengthening the health care system is important
in controlling MDR-TB [29]; unless health system improvements
are actively pursued, the full benefits of the rapid laboratory test
are unlikely to be realised.
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